​

Prestige Consumer Healthcare (PBH) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Prestige Consumer Healthcare Revenue Highlights

Latest Revenue (Y)

$1.13B

Latest Revenue (Q)

$290.32M

Main Segment (Y)

Gastrointestinal

Main Geography (Y)

North American OTC Healthcare

Prestige Consumer Healthcare Revenue by Period

Prestige Consumer Healthcare Revenue by Year

DateRevenueChange
2024-03-31$1.13B-0.21%
2023-03-31$1.13B3.76%
2022-03-31$1.09B15.21%
2021-03-31$943.37M-2.04%
2020-03-31$963.01M-1.31%
2019-03-31$975.78M-6.28%
2018-03-31$1.04B18.04%
2017-03-31$882.06M9.40%
2016-03-31$806.25M12.82%
2015-03-31$714.62M18.73%
2014-03-31$601.88M-3.48%
2013-03-31$623.60M41.38%
2012-03-31$441.08M31.08%
2011-03-31$336.51M11.42%
2010-03-31$302.02M-3.42%
2009-03-31$312.71M-4.25%
2008-03-31$326.60M2.50%
2007-03-31$318.63M7.40%
2006-03-31$296.67M-2.19%
2005-03-31$303.32M244.99%
2004-03-31$87.92M22.56%
2003-03-31$71.73M55.09%
2002-03-31$46.25M434.41%
2001-03-31$8.65M-

Prestige Consumer Healthcare generated $1.13B in revenue during NA 2024, up -0.21% compared to the previous quarter, and up 115.33% compared to the same period a year ago.

Prestige Consumer Healthcare Revenue by Quarter

DateRevenueChange
2024-12-31$290.32M2.39%
2024-09-30$283.55M6.14%
2024-06-30$267.14M-3.56%
2024-03-31$276.99M-2.03%
2023-12-31$282.74M-1.25%
2023-09-30$286.32M2.51%
2023-06-30$279.31M-2.29%
2023-03-31$285.87M3.75%
2022-12-31$275.52M-4.75%
2022-09-30$289.27M4.41%
2022-06-30$277.06M3.79%
2022-03-31$266.94M-2.74%
2021-12-31$274.47M-0.64%
2021-09-30$276.23M2.62%
2021-06-30$269.18M13.21%
2021-03-31$237.76M-0.43%
2020-12-31$238.79M0.58%
2020-09-30$237.42M3.50%
2020-06-30$229.39M-8.69%
2020-03-31$251.24M4.01%
2019-12-31$241.55M1.46%
2019-09-30$238.07M2.55%
2019-06-30$232.15M-3.68%
2019-03-31$241.03M-0.16%
2018-12-31$241.41M0.86%
2018-09-30$239.36M-5.76%
2018-06-30$253.98M-0.78%
2018-03-31$255.97M-5.41%
2017-12-31$270.62M4.88%
2017-09-30$258.03M0.57%
2017-06-30$256.57M6.61%
2017-03-31$240.67M11.03%
2016-12-31$216.76M0.80%
2016-09-30$215.05M2.61%
2016-06-30$209.57M0.83%
2016-03-31$207.85M3.83%
2015-12-31$200.19M-2.85%
2015-09-30$206.06M7.25%
2015-06-30$192.13M1.10%
2015-03-31$190.05M-3.83%
2014-12-31$197.61M9.01%
2014-09-30$181.27M24.41%
2014-06-30$145.70M1.00%
2014-03-31$144.26M-1.34%
2013-12-31$146.21M-13.20%
2013-09-30$168.44M17.82%
2013-06-30$142.97M-7.47%
2013-03-31$154.51M-3.57%
2012-12-31$160.23M-1.00%
2012-09-30$161.85M10.11%
2012-06-30$147.00M9.70%
2012-03-31$134.00M26.11%
2011-12-31$106.25M0.67%
2011-09-30$105.54M10.76%
2011-06-30$95.30M-1.11%
2011-03-31$96.36M6.35%
2010-12-31$90.61M15.71%
2010-09-30$78.30M6.64%
2010-06-30$73.42M2.86%
2010-03-31$71.38M-5.39%
2009-12-31$75.45M-10.37%
2009-09-30$84.18M14.96%
2009-06-30$73.22M3.35%
2009-03-31$70.85M-11.74%
2008-12-31$80.28M-8.83%
2008-09-30$88.05M19.74%
2008-06-30$73.53M-8.58%
2008-03-31$80.43M-

Prestige Consumer Healthcare generated $290.32M in revenue during Q3 2025, up 2.39% compared to the previous quarter, and up 101.40% compared to the same period a year ago.

Prestige Consumer Healthcare Revenue Breakdown

Prestige Consumer Healthcare Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceMar 25Mar 24Mar 23Mar 22Mar 21
Gastrointestinal$255.94M$231.61M---
Oral Care$95.03M$96.31M---
Other OTC$13.78M$12.03M---
Dermatologicals$128.95M$129.10M---
Women's Health$236.83M$240.42M---
Cough and Cold$106.21M$119.02M---
Analgesics$117.70M$117.45M---
Eye and Ear Care$183.32M$179.42M---
Product--$1.13B$1.09B$943.32M
Product and Service, Other--$107.00K$42.00K$41.00K

Prestige Consumer Healthcare's latest annual revenue breakdown by segment (product or service), as of Mar 25: Gastrointestinal (22.50%), Women's Health (20.82%), Eye and Ear Care (16.11%), Dermatologicals (11.33%), Analgesics (10.34%), Cough and Cold (9.34%), Oral Care (8.35%), and Other OTC (1.21%).

Quarterly Revenue by Product

Product/ServiceMar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
Eye and Ear Care$46.73M$45.68M$42.79M$87.48M$45.07M$46.87M--------------
Dermatologicals$29.08M$30.66M$35.85M$66.85M$27.77M$34.49M--------------
Women's Health$63.78M$58.13M$60.35M$120.08M$58.27M$62.07M--------------
Analgesics$30.20M$30.98M$28.22M$55.82M$30.27M$31.36M--------------
Cough and Cold$26.91M$29.33M$29.27M$52.61M$33.17M$33.23M--------------
Other OTC$3.85M$3.48M$3.16M$6.17M$3.11M$2.75M--------------
Oral Care$27.09M$23.08M$24.08M$50.06M$23.46M$22.78M--------------
Gastrointestinal$68.88M$68.99M$60.06M$117.22M$61.63M$52.76M--------------
Product and Service, Other------$10.00K$34.00K$29.00K$9.00K$35.00K$9.00K$16.00K$8.00K$9.00K$9.00K$9.00K$13.00K$10.00K$28.00K
Product------$279.30M$285.83M$275.50M$289.26M$277.02M$266.93M$274.45M$276.22M$269.17M$237.75M$238.78M$237.41M$229.38M$251.21M

Prestige Consumer Healthcare's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Gastrointestinal (23.23%), Women's Health (21.51%), Eye and Ear Care (15.76%), Analgesics (10.18%), Dermatologicals (9.81%), Oral Care (9.14%), Cough and Cold (9.08%), and Other OTC (1.30%).

Prestige Consumer Healthcare Revenue Breakdown by Country

Annual Revenue by Country

CountryMar 25Mar 24Mar 23Mar 22Mar 21
North American OTC Healthcare$960.01M$958.26M---
Non-US--$174.50M$176.71M$144.33M
UNITED STATES--$953.22M$910.11M$799.04M

Prestige Consumer Healthcare's latest annual revenue breakdown by geography, as of Mar 25: North American OTC Healthcare (100.00%).

Quarterly Revenue by Country

CountryMar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
North American OTC Healthcare$248.95M$238.93M$239.81M$422.32M$236.56M$244.42M$54.95M$242.32M$53.92M$59.38M$61.18M---------
UNITED STATES-----------$219.57M$227.72M$236.15M$226.67M$199.11M$197.30M$203.29M$199.35M$208.39M
Non-US-----------$47.36M$46.76M$40.07M$42.51M$38.65M$41.49M$34.13M$30.05M$42.84M

Prestige Consumer Healthcare's latest quarterly revenue breakdown by geography, as of Mar 25: North American OTC Healthcare (100.00%).

Prestige Consumer Healthcare Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
PBHPrestige Consumer Healthcare$1.13B$290.32M
PAHCPhibro Animal Health$977.89M$309.26M
EVOEvotec SE$781.43M$208.73M
AMPHAmphastar Pharmaceuticals$712.81M$186.98M
PCRXPacira BioSciences$700.97M$187.25M
SUPNSupernus Pharmaceuticals$661.82M$174.16M
COLLCollegium Pharmaceutical$631.45M$181.95M
ANIPANI Pharmaceuticals$614.38M$190.57M
RGCRegencell Bioscience--

PBH Revenue FAQ

What is Prestige Consumer Healthcare’s yearly revenue?

Prestige Consumer Healthcare's yearly revenue for 2024 was $1.13B, representing a decrease of -0.21% compared to 2023. The company's yearly revenue for 2023 was $1.13B, representing an increase of 3.76% compared to 2022. PBH's yearly revenue for 2022 was $1.09B, representing an increase of 15.21% compared to 2021.

What is Prestige Consumer Healthcare’s quarterly revenue?

Prestige Consumer Healthcare's quarterly revenue for Q3 2025 was $290.32M, a 2.39% increase from the previous quarter (Q2 2025), and a 2.68% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $283.55M, a 6.14% increase from the previous quarter (Q1 2025), and a -0.97% decrease year-over-year (Q2 2024). PBH's quarterly revenue for Q1 2025 was $267.14M, a -3.56% decrease from the previous quarter (Q4 2024), and a -4.36% decrease year-over-year (Q1 2024).

What is Prestige Consumer Healthcare’s revenue growth rate?

Prestige Consumer Healthcare's revenue growth rate for the last 3 years (2022-2024) was 3.55%, and for the last 5 years (2020-2024) was 16.86%.

What are Prestige Consumer Healthcare’s revenue streams?

Prestige Consumer Healthcare's revenue streams in r 25 are Gastrointestinal, Oral Care, Other OTC, Dermatologicals, Women's Health, Cough and Cold, Analgesics, and Eye and Ear Care. Gastrointestinal generated $255.94M in revenue, accounting 22.50% of the company's total revenue, up 10.51% year-over-year. Oral Care generated $95.03M in revenue, accounting 8.35% of the company's total revenue, down -1.32% year-over-year. Other OTC generated $13.78M in revenue, accounting 1.21% of the company's total revenue, up 14.58% year-over-year. Dermatologicals generated $128.95M in revenue, accounting 11.33% of the company's total revenue, down -0.12% year-over-year. Women's Health generated $236.83M in revenue, accounting 20.82% of the company's total revenue, down -1.49% year-over-year. Cough and Cold generated $106.21M in revenue, accounting 9.34% of the company's total revenue, down -10.76% year-over-year. Analgesics generated $117.7M in revenue, accounting 10.34% of the company's total revenue, up 0.21% year-over-year. Eye and Ear Care generated $183.32M in revenue, accounting 16.11% of the company's total revenue, up 2.17% year-over-year.

What is Prestige Consumer Healthcare’s main source of revenue?

For the fiscal year ending Mar 25, the largest source of revenue of Prestige Consumer Healthcare was Gastrointestinal. This segment made a revenue of $255.94M, representing 22.50% of the company's total revenue.